Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1999 Feb;54(2):161–168. doi: 10.1136/thx.54.2.161

Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension

P Egermayer 1, G Town 1, A Peacock 1
PMCID: PMC1745408  PMID: 10325923

Full Text

The Full Text of this article is available as a PDF (158.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., Higenbottam T., Oakley C., Wouters E., Aubier M. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996 Aug 29;335(9):609–616. doi: 10.1056/NEJM199608293350901. [DOI] [PubMed] [Google Scholar]
  2. Alpert J. S., Irwin R. S., Dalen J. E. Pulmonary hypertension. Curr Probl Cardiol. 1981 Jan;5(10):1–39. doi: 10.1016/0146-2806(81)90012-8. [DOI] [PubMed] [Google Scholar]
  3. Arnett E. N., Battle W. E., Russo J. V., Roberts W. C. Intravenous injection of talc-containing drugs intended for oral use. A cause of pulmonary granulomatosis and pulmonary hypertension. Am J Med. 1976 May 10;60(5):711–718. doi: 10.1016/0002-9343(76)90508-8. [DOI] [PubMed] [Google Scholar]
  4. Arora R. R., Warner R. R. Do indole markers predict carcinoid heart disease? Chest. 1986 Jul;90(1):87–89. doi: 10.1378/chest.90.1.87. [DOI] [PubMed] [Google Scholar]
  5. Asherson R. A., Oakley C. M. Pulmonary hypertension and systemic lupus erythematosus. J Rheumatol. 1986 Feb;13(1):1–5. [PubMed] [Google Scholar]
  6. Auger W. R., Permpikul P., Moser K. M. Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: a preliminary report. Am J Med. 1995 Oct;99(4):392–396. doi: 10.1016/s0002-9343(99)80187-9. [DOI] [PubMed] [Google Scholar]
  7. Baguley B. C., Zhuang L., Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol Res. 1997;9(2):55–60. [PubMed] [Google Scholar]
  8. Battle R. W., Davitt M. A., Cooper S. M., Buckley L. M., Leib E. S., Beglin P. A., Tischler M. D. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest. 1996 Dec;110(6):1515–1519. doi: 10.1378/chest.110.6.1515. [DOI] [PubMed] [Google Scholar]
  9. Bennett J. S., Kolodziej M. A. Disorders of platelet function. Dis Mon. 1992 Aug;38(8):577–631. [PubMed] [Google Scholar]
  10. Block E. R., Stalcup S. A. Metabolic functions of the lung. Of what clinical relevance? Chest. 1982 Feb;81(2):215–223. doi: 10.1378/chest.81.2.215. [DOI] [PubMed] [Google Scholar]
  11. Bobrov V. A., Fushtei I. M., Polivoda S. N. Legochnaia gemodinamika i serotonin u bol'nykh khronicheskoi pnevmoniei s arterial'noi gipertenziei. Vrach Delo. 1985 Dec;(12):33–35. [PubMed] [Google Scholar]
  12. Bone R. C., Francis P. B., Pierce A. K. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med. 1976 Nov;61(5):585–589. doi: 10.1016/0002-9343(76)90135-2. [DOI] [PubMed] [Google Scholar]
  13. Booker P. D., Evans C., Franks R. Comparison of the haemodynamic effects of dopamine and dobutamine in young children undergoing cardiac surgery. Br J Anaesth. 1995 Apr;74(4):419–423. doi: 10.1093/bja/74.4.419. [DOI] [PubMed] [Google Scholar]
  14. Boor P. J., Hysmith R. M., Sanduja R. A role for a new vascular enzyme in the metabolism of xenobiotic amines. Circ Res. 1990 Jan;66(1):249–252. doi: 10.1161/01.res.66.1.249. [DOI] [PubMed] [Google Scholar]
  15. Bremer K. 5-Hydroxytryptamine (serotonin) subtype 3 antagonists, a major step in prophylaxis and control of cytostatic and radiation-induced emesis. J Cancer Res Clin Oncol. 1991;117(1):85–87. doi: 10.1007/BF01613203. [DOI] [PubMed] [Google Scholar]
  16. Brenot F., Herve P., Petitpretz P., Parent F., Duroux P., Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J. 1993 Dec;70(6):537–541. doi: 10.1136/hrt.70.6.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Breuer J., Georgaraki A., Sieverding L., Baden W., Apitz J. Increased turnover of serotonin in children with pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol. 1996 Jul-Aug;17(4):214–219. doi: 10.1007/BF02524796. [DOI] [PubMed] [Google Scholar]
  18. Breuer J., Meschig R., Breuer H. W., Arnold G. Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin. J Cardiovasc Pharmacol. 1985;7 (Suppl 7):S64–S66. doi: 10.1097/00005344-198500077-00019. [DOI] [PubMed] [Google Scholar]
  19. Breuer J., Meschig R., Breuer H. W., Arnold G. Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin. J Cardiovasc Pharmacol. 1985;7 (Suppl 7):S64–S66. doi: 10.1097/00005344-198500077-00019. [DOI] [PubMed] [Google Scholar]
  20. Brogden R. N., Sorkin E. M. Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. Drugs. 1990 Dec;40(6):903–949. doi: 10.2165/00003495-199040060-00010. [DOI] [PubMed] [Google Scholar]
  21. Buckner C. K., Dea D., Liberati N., Krell R. D. A pharmacologic examination of receptors mediating serotonin-induced bronchoconstriction in the anesthetized guinea pig. J Pharmacol Exp Ther. 1991 Apr;257(1):26–34. [PubMed] [Google Scholar]
  22. COMROE J. H., Jr, VAN LINGEN B., STROUD R. C., RONCORONI A. Reflex and direct cardiopulmonary effects of 5-OH-tryptamine (serotonin); their possible role in pulmonary embolism and coronary thrombosis. Am J Physiol. 1953 Jun;173(3):379–386. doi: 10.1152/ajplegacy.1953.173.3.379. [DOI] [PubMed] [Google Scholar]
  23. Carvalho A. C., Quinn D. A., DeMarinis S. M., Beitz J. G., Zapol W. M. Platelet function in acute respiratory failure. Am J Hematol. 1987 Aug;25(4):377–388. doi: 10.1002/ajh.2830250404. [DOI] [PubMed] [Google Scholar]
  24. Chaouat A., Weitzenblum E., Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Eur Respir J. 1996 Feb;9(2):356–363. doi: 10.1183/09031936.96.09020356. [DOI] [PubMed] [Google Scholar]
  25. Collazos J., Martínez E., Fernández A., Mayo J. Acute, reversible pulmonary hypertension associated with cocaine use. Respir Med. 1996 Mar;90(3):171–174. doi: 10.1016/s0954-6111(96)90160-2. [DOI] [PubMed] [Google Scholar]
  26. Connolly H. M., Crary J. L., McGoon M. D., Hensrud D. D., Edwards B. S., Edwards W. D., Schaff H. V. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997 Aug 28;337(9):581–588. doi: 10.1056/NEJM199708283370901. [DOI] [PubMed] [Google Scholar]
  27. Constantinides P., Robinson M. Ultrastructural injury of arterial endothelium. II. Effects of vasoactive amines. Arch Pathol. 1969 Aug;88(2):106–112. [PubMed] [Google Scholar]
  28. Cooke J. P., Dzau V. J. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997;48:489–509. doi: 10.1146/annurev.med.48.1.489. [DOI] [PubMed] [Google Scholar]
  29. Cool C. D., Kennedy D., Voelkel N. F., Tuder R. M. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol. 1997 Apr;28(4):434–442. doi: 10.1016/s0046-8177(97)90032-0. [DOI] [PubMed] [Google Scholar]
  30. Cooper R., Ghali J., Simmons B. E., Castaner A. Elevated pulmonary artery pressure. An independent predictor of mortality. Chest. 1991 Jan;99(1):112–120. doi: 10.1378/chest.99.1.112. [DOI] [PubMed] [Google Scholar]
  31. Demiryurek A. T., Wadsworth R. M., Kane K. A., Peacock A. J. The role of endothelium in hypoxic constriction of human pulmonary artery rings. Am Rev Respir Dis. 1993 Feb;147(2):283–290. doi: 10.1164/ajrccm/147.2.283. [DOI] [PubMed] [Google Scholar]
  32. Demling R. H., Wong C., Fox R., Hechtman H., Huval W. Relationship of increased lung serotonin levels to endotoxin-induced pulmonary hypertension in sheep. Effect of a serotonin antagonist. Am Rev Respir Dis. 1985 Dec;132(6):1257–1261. doi: 10.1164/arrd.1985.132.6.1257. [DOI] [PubMed] [Google Scholar]
  33. Desmecht D., Linden A., Amory H., Lekeux P. Hemodynamic responses to Pasteurella haemolytica inoculation in calves given type 2 serotonergic antagonist. Can J Physiol Pharmacol. 1996 May;74(5):572–579. [PubMed] [Google Scholar]
  34. Draughn D., Morris D. M. Sustained pulmonary hypertension in surgical patients. Am Surg. 1993 Jun;59(6):346–349. [PubMed] [Google Scholar]
  35. Drouet L., Bal Dit Sollier C., Ruton S., Pignaud G. Role of serotonin in arteriolar thrombosis and secondary vasospasm. J Cardiovasc Pharmacol. 1990;16 (Suppl 3):S49–S53. [PubMed] [Google Scholar]
  36. Eckhauser F. E., Argenta L. C., Strodel W. E., Wheeler R. H., Bull F. E., Appelman H. D., Thompson N. W. Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery. 1981 Oct;90(4):720–728. [PubMed] [Google Scholar]
  37. Eddahibi S., Raffestin B., Pham I., Launay J. M., Aegerter P., Sitbon M., Adnot S. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol. 1997 Mar;272(3 Pt 2):H1173–H1181. doi: 10.1152/ajpheart.1997.272.3.H1173. [DOI] [PubMed] [Google Scholar]
  38. Edwards B. S., Weir E. K., Edwards W. D., Ludwig J., Dykoski R. K., Edwards J. E. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol. 1987 Dec;10(6):1233–1238. doi: 10.1016/s0735-1097(87)80123-7. [DOI] [PubMed] [Google Scholar]
  39. Farber H. W., Falls R., Glauser F. L. Transient pulmonary hypertension from the intravenous injection of crushed, suspended pentazocine tablets. Chest. 1981 Aug;80(2):178–182. doi: 10.1378/chest.80.2.178. [DOI] [PubMed] [Google Scholar]
  40. Fein A. M., Lippmann M., Holtzman H., Eliraz A., Goldberg S. K. The risk factors, incidence, and prognosis of ARDS following septicemia. Chest. 1983 Jan;83(1):40–42. doi: 10.1378/chest.83.1.40. [DOI] [PubMed] [Google Scholar]
  41. Filtenborg J. A. Persistent pulmonary hypertension after lithium intoxication in the newborn. Eur J Pediatr. 1982 Jul;138(4):321–323. doi: 10.1007/BF00442508. [DOI] [PubMed] [Google Scholar]
  42. Fowler A. A., Hamman R. F., Zerbe G. O., Benson K. N., Hyers T. M. Adult respiratory distress syndrome. Prognosis after onset. Am Rev Respir Dis. 1985 Sep;132(3):472–478. doi: 10.1164/arrd.1985.132.3.472. [DOI] [PubMed] [Google Scholar]
  43. Frishman W. H., Huberfeld S., Okin S., Wang Y. H., Kumar A., Shareef B. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol. 1995 Jun;35(6):541–572. doi: 10.1002/j.1552-4604.1995.tb05013.x. [DOI] [PubMed] [Google Scholar]
  44. Friström S., Airaksinen M. M., Halmekoski J. Release of platelet 5-hydroxytryptamine by some anorexic and other sympathomimetics and their acetyl derivatives. Acta Pharmacol Toxicol (Copenh) 1977 Sep;41(3):218–224. doi: 10.1111/j.1600-0773.1977.tb02142.x. [DOI] [PubMed] [Google Scholar]
  45. Fujiwara M., Tobise K., Onodera S. [Effects of methysergide on pulmonary circulation]. Hokkaido Igaku Zasshi. 1983 Sep;58(5):541–552. [PubMed] [Google Scholar]
  46. Ganey P. E., Sprugel K. H., White S. M., Wagner J. G., Roth R. A. Pulmonary hypertension due to monocrotaline pyrrole is reduced by moderate thrombocytopenia. Am J Physiol. 1988 Nov;255(5 Pt 2):H1165–H1172. doi: 10.1152/ajpheart.1988.255.5.H1165. [DOI] [PubMed] [Google Scholar]
  47. Gaudin P. B., Rosai J. Florid vascular proliferation associated with neural and neuroendocrine neoplasms. A diagnostic clue and potential pitfall. Am J Surg Pathol. 1995 Jun;19(6):642–652. [PubMed] [Google Scholar]
  48. Gillette S. M., Powers B. E., Orton E. C., Gillette E. L. Early radiation response of the canine heart and lung. Radiat Res. 1991 Jan;125(1):34–40. [PubMed] [Google Scholar]
  49. Gosney J., Heath D., Smith P., Harris P., Yacoub M. Pulmonary endocrine cells in pulmonary arterial disease. Arch Pathol Lab Med. 1989 Apr;113(4):337–341. [PubMed] [Google Scholar]
  50. Gralnick H. R., Vail M., McKeown L. P., Merryman P., Wilson O., Chu I., Kimball J. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1995 Nov;91(3):697–702. doi: 10.1111/j.1365-2141.1995.tb05371.x. [DOI] [PubMed] [Google Scholar]
  51. Gurewich V., Cohen M. L., Thomas D. P. Humoral factors in massive pulmonary embolism: an experimental study. Am Heart J. 1968 Dec;76(6):784–794. doi: 10.1016/0002-8703(68)90264-0. [DOI] [PubMed] [Google Scholar]
  52. Gyermek L. Pharmacology of serotonin as related to anesthesia. J Clin Anesth. 1996 Aug;8(5):402–425. doi: 10.1016/0952-8180(96)00093-1. [DOI] [PubMed] [Google Scholar]
  53. Hadengue A., Benhayoun M. K., Lebrec D., Benhamou J. P. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology. 1991 Feb;100(2):520–528. doi: 10.1016/0016-5085(91)90225-a. [DOI] [PubMed] [Google Scholar]
  54. Hamet A., Král B., Cernohorský D. Comparative effects of oxygen, nifedipine and ketanserin in hypoxic pulmonary hypertension. Cor Vasa. 1985;27(6):406–411. [PubMed] [Google Scholar]
  55. Hamilton W. M., Nemir P., Jr The humoral factor in pulmonary embolism. Arch Surg. 1972 Oct;105(4):593–598. doi: 10.1001/archsurg.1972.04180100040011. [DOI] [PubMed] [Google Scholar]
  56. Hart C. M., Block E. R. Lung serotonin metabolism. Clin Chest Med. 1989 Mar;10(1):59–70. [PubMed] [Google Scholar]
  57. Hauck A. J., Edwards W. D., Danielson G. K., Mullany C. J., Bresnahan D. R. Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature. Arch Pathol Lab Med. 1990 Jan;114(1):62–64. [PubMed] [Google Scholar]
  58. Heffner J. E., Sahn S. A., Repine J. E. The role of platelets in the adult respiratory distress syndrome. Culprits or bystanders? Am Rev Respir Dis. 1987 Feb;135(2):482–492. doi: 10.1164/arrd.1987.135.2.482. [DOI] [PubMed] [Google Scholar]
  59. Heller P. G., Grinberg A. R., Lencioni M., Molina M. M., Roncoroni A. J. Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. Chest. 1992 Aug;102(2):642–643. doi: 10.1378/chest.102.2.642. [DOI] [PubMed] [Google Scholar]
  60. Herve P., Drouet L., Dosquet C., Launay J. M., Rain B., Simonneau G., Caen J., Duroux P. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med. 1990 Jul;89(1):117–120. doi: 10.1016/0002-9343(90)90111-p. [DOI] [PubMed] [Google Scholar]
  61. Hervé P., Launay J. M., Scrobohaci M. L., Brenot F., Simonneau G., Petitpretz P., Poubeau P., Cerrina J., Duroux P., Drouet L. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995 Sep;99(3):249–254. doi: 10.1016/s0002-9343(99)80156-9. [DOI] [PubMed] [Google Scholar]
  62. Hillerdal G. The lung physician and the antiphospholipid syndrome. Eur Respir J. 1997 Mar;10(3):511–512. [PubMed] [Google Scholar]
  63. Hilliker K. S., Bell T. G., Roth R. A. Monocrotaline pyrrole-induced pulmonary hypertension in fawn-hooded rats with platelet storage pool deficiency: 5-hydroxytryptamine uptake by isolated, perfused lungs. Thromb Haemost. 1983 Dec 30;50(4):844–847. [PubMed] [Google Scholar]
  64. Hilliker K. S., Roth R. A. Alteration of monocrotaline pyrrole-induced cardiopulmonary effects in rats by hydrallazine, dexamethasone or sulphinpyrazone. Br J Pharmacol. 1984 Jun;82(2):375–380. doi: 10.1111/j.1476-5381.1984.tb10772.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Horgan M. J., Carrasco N. J., Risemberg H. The relationship of thrombocytopenia to the onset of persistent pulmonary hypertension of the newborn in the meconium aspiration syndrome. N Y State J Med. 1985 Jun;85(6):245–247. [PubMed] [Google Scholar]
  66. Huet Y., Brun-Buisson C., Lemaire F., Teisseire B., Lhoste F., Rapin M. Cardiopulmonary effects of ketanserin infusion in human pulmonary embolism. Am Rev Respir Dis. 1987 Jan;135(1):114–117. doi: 10.1164/arrd.1987.135.1.114. [DOI] [PubMed] [Google Scholar]
  67. Huval W. V., Lelcuk S., Feingold H., Valeri C. R., Shepro D., Hechtman H. B. Effects of nitroprusside and ketanserin upon pulmonary edema after acid injury. Surg Gynecol Obstet. 1988 Jun;166(6):527–534. [PubMed] [Google Scholar]
  68. Huval W. V., Mathieson M. A., Stemp L. I., Dunham B. M., Jones A. G., Shepro D., Hechtman H. B. Therapeutic benefits of 5-hydroxytryptamine inhibition following pulmonary embolism. Ann Surg. 1983 Feb;197(2):220–225. doi: 10.1097/00000658-198302000-00016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Jacobsen M. B., Nitter-Hauge S., Bryde P. E., Hanssen L. E. Cardiac manifestations in mid-gut carcinoid disease. Eur Heart J. 1995 Feb;16(2):263–268. doi: 10.1093/oxfordjournals.eurheartj.a060894. [DOI] [PubMed] [Google Scholar]
  70. Johnson D. E., Georgieff M. K. Pulmonary neuroendocrine cells. Their secretory products and their potential roles in health and chronic lung disease in infancy. Am Rev Respir Dis. 1989 Dec;140(6):1807–1812. doi: 10.1164/ajrccm/140.6.1807. [DOI] [PubMed] [Google Scholar]
  71. Jubelirer S. J. Primary pulmonary hypertension. Its association with microangiopathic hemolytic anemia and thrombocytopenia. Arch Intern Med. 1991 Jun;151(6):1221–1223. doi: 10.1001/archinte.151.6.1221. [DOI] [PubMed] [Google Scholar]
  72. Kanai Y., Hori S., Tanaka T., Yasuoka M., Watanabe K., Aikawa N., Hosoda Y. Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats. Cardiovasc Res. 1993 Sep;27(9):1619–1623. doi: 10.1093/cvr/27.9.1619. [DOI] [PubMed] [Google Scholar]
  73. Katz A. I., Massry S. G., Tikva P. Arteriospasm after ergotamine tartrate in infectious hepatitis. Arch Intern Med. 1966 Jul;118(1):62–64. [PubMed] [Google Scholar]
  74. Kawai A., Umeda A., Mori M., Takasugi T., Asano K., Tanaka T., Yasuoka M., Yamaguchi K. [Role of serotonin in impaired gas exchange during pulmonary embolism]. Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Sep;33(9):947–955. [PubMed] [Google Scholar]
  75. Kay J. M., Keane P. M., Suyama K. L. Pulmonary hypertension induced in rats by monocrotaline and chronic hypoxia is reduced by p-chlorophenylalanine. Respiration. 1985;47(1):48–56. doi: 10.1159/000194748. [DOI] [PubMed] [Google Scholar]
  76. Keith I. M., Will J. A., Huxtable R. J., Weir K. Anti-platelet agents reduce morphological changes of chronic hypoxic pulmonary hypertension. Histol Histopathol. 1987 Apr;2(2):203–206. [PubMed] [Google Scholar]
  77. Keith I., Day R., Lemaire S., Lemaire I. Asbestos-induced fibrosis in rats: increase in lung mast cells and autacoid contents. Exp Lung Res. 1987;13(3):311–327. doi: 10.3109/01902148709069596. [DOI] [PubMed] [Google Scholar]
  78. Keller C. A., Shepard J. W., Jr, Chun D. S., Vasquez P., Dolan G. F. Pulmonary hypertension in chronic obstructive pulmonary disease. Multivariate analysis. Chest. 1986 Aug;90(2):185–192. doi: 10.1378/chest.90.2.185. [DOI] [PubMed] [Google Scholar]
  79. King A. D., Bell S. D., Stuttle A. W., Carpani de Kaski M., Peters A. M., Lavender J. P. Platelet imaging of thromboembolism. Natural history of postoperative deep venous thrombosis and pulmonary embolism illustrated using the 111In-labelled platelet-specific monoclonal antibody, P256. Chest. 1992 Jun;101(6):1597–1600. doi: 10.1378/chest.101.6.1597. [DOI] [PubMed] [Google Scholar]
  80. Klimiuk P. S., Grennan A., Weinkove C., Jayson M. I. Platelet serotonin in systemic sclerosis. Ann Rheum Dis. 1989 Jul;48(7):586–589. doi: 10.1136/ard.48.7.586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Kusajima K., Ozdemir I. A., Webb W. R., Wax S. D., Parker F. B., Jr Role of serotonin and serotonin antagonist on pulmonary hemodynamics and microcirculation in hemorrhagic shock. J Thorac Cardiovasc Surg. 1974 Jun;67(6):908–914. [PubMed] [Google Scholar]
  82. Langleben D., Carvalho A. C., Reid L. M. The platelet thromboxane inhibitor, dazmegrel, does not reduce monocrotaline-induced pulmonary hypertension. Am Rev Respir Dis. 1986 May;133(5):789–791. [PubMed] [Google Scholar]
  83. Lauweryns J. M., de Bock V., Guelinckx P., Decramer M. Effects of unilateral hypoxia on neuroepithelial bodies in rabbit lungs. J Appl Physiol Respir Environ Exerc Physiol. 1983 Dec;55(6):1665–1668. doi: 10.1152/jappl.1983.55.6.1665. [DOI] [PubMed] [Google Scholar]
  84. Lee S. L., Wang W. W., Joseph P. M., Hales C. A., Fanburg B. L. Inhibitory effect of heparin on serotonin-induced hyperplasia and hypertrophy of smooth muscle cells. Am J Respir Cell Mol Biol. 1997 Jul;17(1):78–83. doi: 10.1165/ajrcmb.17.1.2727. [DOI] [PubMed] [Google Scholar]
  85. Lockhart A. Pulmonary arterial hypertension in portal hypertension. Clin Gastroenterol. 1985 Jan;14(1):123–138. [PubMed] [Google Scholar]
  86. Lundin L., Oberg K., Landelius J., Hansson H. E., Wilander E., Theodorsson E. Plasma atrial natriuretic peptide in carcinoid heart disease. Am J Cardiol. 1989 Apr 15;63(13):969–972. doi: 10.1016/0002-9149(89)90150-1. [DOI] [PubMed] [Google Scholar]
  87. MacLean M. R., Clayton R. A., Hillis S. W., McIntyre P. D., Peacock A. J., Templeton A. G. 5-HT1-receptor-mediated vasoconstriction in bovine isolated pulmonary arteries: influences of vascular endothelium and tone. Pulm Pharmacol. 1994 Feb;7(1):65–72. doi: 10.1006/pulp.1994.1007. [DOI] [PubMed] [Google Scholar]
  88. Madden B. P., Gosney J., Coghlan J. G., Kamalvand K., Caslin A. W., Smith P., Yacoub M., Heath D. Pretransplant clinicopathological correlation in end-stage primary pulmonary hypertension. Eur Respir J. 1994 Apr;7(4):672–678. doi: 10.1183/09031936.94.07040672. [DOI] [PubMed] [Google Scholar]
  89. Mandell M. S., Groves B. M. Pulmonary hypertension in chronic liver disease. Clin Chest Med. 1996 Mar;17(1):17–33. doi: 10.1016/s0272-5231(05)70296-3. [DOI] [PubMed] [Google Scholar]
  90. Marasini B., Biondi M. L., Bianchi E., Dell'Orto P., Agostoni A. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon. Eur J Clin Pharmacol. 1988;35(4):419–421. doi: 10.1007/BF00561375. [DOI] [PubMed] [Google Scholar]
  91. Martin T. R., Cohen M. L., Drazen J. M. Serotonin-induced pulmonary responses are mediated by the 5-HT2 receptor in the mouse. J Pharmacol Exp Ther. 1994 Jan;268(1):104–109. [PubMed] [Google Scholar]
  92. McFadden E. P., Clarke J. G., Davies G. J., Kaski J. C., Haider A. W., Maseri A. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med. 1991 Mar 7;324(10):648–654. doi: 10.1056/NEJM199103073241002. [DOI] [PubMed] [Google Scholar]
  93. McGoon M. D., Vanhoutte P. M. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest. 1984 Sep;74(3):828–833. doi: 10.1172/JCI111499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. McGoon M. D., Vlietstra R. E. Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension. Int J Cardiol. 1987 Mar;14(3):303–309. doi: 10.1016/0167-5273(87)90200-2. [DOI] [PubMed] [Google Scholar]
  95. McGoon M. D., Vlietstra R. E. Vasodilator therapy for primary pulmonary hypertension. Mayo Clin Proc. 1984 Oct;59(10):672–677. doi: 10.1016/s0025-6196(12)62055-2. [DOI] [PubMed] [Google Scholar]
  96. Mielke H., Seiler K. U., Stumpf U., Wassermann O. Uber eine Beziehung zwischen dem Serotoninstoffwechsel und der pulmonalen Hypertonie bei Ratten nach Gabe verschiedener Anorektika. Z Kardiol. 1973 Dec;62(12):1090–1098. [PubMed] [Google Scholar]
  97. Mills K. C. Serotonin syndrome. A clinical update. Crit Care Clin. 1997 Oct;13(4):763–783. doi: 10.1016/s0749-0704(05)70368-7. [DOI] [PubMed] [Google Scholar]
  98. Mlczoch J., Tucker A., Weir E. K., Reeves J. T., Grover R. F. Platelet-mediated pulmonary hypertension and hypoxia during pulmonary microembolism: reduction by platelet inhibition. Chest. 1978 Dec;74(6):648–653. doi: 10.1378/chest.74.6.648. [DOI] [PubMed] [Google Scholar]
  99. Monreal M., Lafoz E., Casals A., Ruíz J., Arias A. Platelet count and venous thromboembolism. A useful test for suspected pulmonary embolism. Chest. 1991 Dec;100(6):1493–1496. doi: 10.1378/chest.100.6.1493. [DOI] [PubMed] [Google Scholar]
  100. Moore A., Nachman R. L. Platelet Fc receptor. Increased expression in myeloproliferative disease. J Clin Invest. 1981 Apr;67(4):1064–1071. doi: 10.1172/JCI110118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Moore G. W., Smith R. R., Hutchins G. M. Pulmonary artery atherosclerosis: correlation with systemic atherosclerosis and hypertensive pulmonary vascular disease. Arch Pathol Lab Med. 1982 Aug;106(8):378–380. [PubMed] [Google Scholar]
  102. Moore L. K., Burt J. M. Gap junction function in vascular smooth muscle: influence of serotonin. Am J Physiol. 1995 Oct;269(4 Pt 2):H1481–H1489. doi: 10.1152/ajpheart.1995.269.4.H1481. [DOI] [PubMed] [Google Scholar]
  103. Morcos N. C., Purdy R. E., Henry W. L. Vasoreactivity in isolated perfused atherosclerotic human coronary arteries. Int J Tissue React. 1988;10(3):159–167. [PubMed] [Google Scholar]
  104. Murata I., Takenaka K., Yoshinoya S., Kikuchi K., Kiuchi T., Tanigawa T., Ito K. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest. 1997 Jan;111(1):36–43. doi: 10.1378/chest.111.1.36. [DOI] [PubMed] [Google Scholar]
  105. Naeije R., Maggiorini M., Delcroix M., Leeman M., Mélot C. Effects of chronic dexfenfluramine treatment on pulmonary hemodynamics in dogs. Am J Respir Crit Care Med. 1996 Nov;154(5):1347–1350. doi: 10.1164/ajrccm.154.5.8912746. [DOI] [PubMed] [Google Scholar]
  106. Nakano T., Miyamoto K., Nishimura M., Aida A., Aoi K., Kawakami Y. Role of pulmonary intravascular macrophages in anti-platelet serum-induced pulmonary hypertension in sheep. Respir Physiol. 1994 Sep;98(1):83–99. doi: 10.1016/0034-5687(94)90038-8. [DOI] [PubMed] [Google Scholar]
  107. Nakonechnicov S., Gabbasov Z., Chazova I., Popov E., Belenkov Y. u. Platelet aggregation in patients with primary pulmonary hypertension. Blood Coagul Fibrinolysis. 1996 Mar;7(2):225–227. doi: 10.1097/00001721-199603000-00029. [DOI] [PubMed] [Google Scholar]
  108. Nenci G. G., Berrettini M., Todisco T., Costantini V., Grasselli S. Exhausted platelets in chronic obstructive pulmonary disease. Respiration. 1983;44(1):71–76. doi: 10.1159/000194530. [DOI] [PubMed] [Google Scholar]
  109. Nenci G. G., Berrettini M., Todisco T., Costantini V., Parise P. Effects of dipyridamole on the hypoxemic pulmonary hypertension of patients with chronic obstructive pulmonary disease. Respiration. 1988;53(1):13–19. doi: 10.1159/000195390. [DOI] [PubMed] [Google Scholar]
  110. Olson N. C. Role of 5-hydroxytryptamine in endotoxin-induced respiratory failure of pigs. Am Rev Respir Dis. 1987 Jan;135(1):93–99. doi: 10.1164/arrd.1987.135.1.93. [DOI] [PubMed] [Google Scholar]
  111. Onodera S. [Pulmonary vasoconstrictor responses]. Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Dec;30 (Suppl):15–25. [PubMed] [Google Scholar]
  112. Pakala R., Willerson J. T., Benedict C. R. Mitogenic effect of serotonin on vascular endothelial cells. Circulation. 1994 Oct;90(4):1919–1926. doi: 10.1161/01.cir.90.4.1919. [DOI] [PubMed] [Google Scholar]
  113. Peterson L. M., Evans M. L., Graham M. M., Eary J. F., Dahlen D. D. Vascular response to radiation injury in the rat lung. Radiat Res. 1992 Feb;129(2):139–148. [PubMed] [Google Scholar]
  114. Pribilova N. N. Obmen serotonina i legochnaia gipertenziia pri khronicheskikh nespetsificheskikh zabolevaniiakh legkikh. Sov Med. 1976 Dec;(12):107–111. [PubMed] [Google Scholar]
  115. Rabinovitch M., Andrew M., Thom H., Trusler G. A., Williams W. G., Rowe R. D., Olley P. M. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation. 1987 Nov;76(5):1043–1052. doi: 10.1161/01.cir.76.5.1043. [DOI] [PubMed] [Google Scholar]
  116. Rabinovitch M. Investigational approaches to pulmonary hypertension. Toxicol Pathol. 1991;19(4 Pt 1):458–469. doi: 10.1177/019262339101900414. [DOI] [PubMed] [Google Scholar]
  117. Radermacher P., Huet Y., Pluskwa F., Herigault R., Mal H., Teisseire B., Lemaire F. Comparison of ketanserin and sodium nitroprusside in patients with severe ARDS. Anesthesiology. 1988 Jan;68(1):152–157. doi: 10.1097/00000542-198801000-00030. [DOI] [PubMed] [Google Scholar]
  118. Radha T. G., Venkitasubramanian T. A., Viswanathan R. Effect of acute hypoxia on blood serotonin in human beings and rats. Respiration. 1976;33(1):64–69. doi: 10.1159/000193689. [DOI] [PubMed] [Google Scholar]
  119. Radow S. K., Nachamkin I., Morrow C., Fairman R. P., Fratkin M., Rodriguez G. E., Glauser F. L. Foreign body granulomatosis. Clinical and immunologic findings. Am Rev Respir Dis. 1983 May;127(5):575–580. doi: 10.1164/arrd.1983.127.5.575. [DOI] [PubMed] [Google Scholar]
  120. Ran P. X., Duan S. F. [The effects of persantine on pulmonary arterial pressure of rats exposed to hypoxia]. Zhonghua Jie He He Hu Xi Za Zhi. 1993 Aug;16(4):216-7, 252-3. [PubMed] [Google Scholar]
  121. Reid L. M. Structure and function in pulmonary hypertension. New perceptions. Chest. 1986 Feb;89(2):279–288. doi: 10.1378/chest.89.2.279. [DOI] [PubMed] [Google Scholar]
  122. Reisner S. A., Rinkevich D., Markiewicz W., Tatarsky I., Brenner B. Cardiac involvement in patients with myeloproliferative disorders. Am J Med. 1992 Nov;93(5):498–504. doi: 10.1016/0002-9343(92)90576-w. [DOI] [PubMed] [Google Scholar]
  123. Reneman R. S., van der Starre P. J. Serotonin and acute cardiovascular disorders. Cardiovasc Drugs Ther. 1990 Jan;4 (Suppl 1):19–25. doi: 10.1007/BF00053422. [DOI] [PubMed] [Google Scholar]
  124. Robiolio P. A., Rigolin V. H., Wilson J. S., Harrison J. K., Sanders L. L., Bashore T. M., Feldman J. M. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995 Aug 15;92(4):790–795. doi: 10.1161/01.cir.92.4.790. [DOI] [PubMed] [Google Scholar]
  125. Rostagno C., Prisco D., Boddi M., Poggesi L. Evidence for local platelet activation in pulmonary vessels in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Eur Respir J. 1991 Feb;4(2):147–151. [PubMed] [Google Scholar]
  126. Roth R. A., Ganey P. E. Platelets and the puzzles of pulmonary pyrrolizidine poisoning. Toxicol Appl Pharmacol. 1988 May;93(3):463–471. doi: 10.1016/0041-008x(88)90050-6. [DOI] [PubMed] [Google Scholar]
  127. Rounds S., Hill N. S. Pulmonary hypertensive diseases. Chest. 1984 Mar;85(3):397–405. doi: 10.1378/chest.85.3.397. [DOI] [PubMed] [Google Scholar]
  128. SMITH G., SMITH A. N. The role of serotonin in experimental pulmonary embolism. Surg Gynecol Obstet. 1955 Dec;101(6):691–700. [PubMed] [Google Scholar]
  129. Sato K., Webb S., Tucker A., Rabinovitch M., O'Brien R. F., McMurtry I. F., Stelzner T. J. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):793–797. doi: 10.1164/ajrccm/145.4_Pt_1.793. [DOI] [PubMed] [Google Scholar]
  130. Schafer A. I. Bleeding and thrombosis in the myeloproliferative disorders. Blood. 1984 Jul;64(1):1–12. [PubMed] [Google Scholar]
  131. Schafer A. I., Kroll M. H. Nonatheromatous arterial thrombosis. Annu Rev Med. 1993;44:155–170. doi: 10.1146/annurev.me.44.020193.001103. [DOI] [PubMed] [Google Scholar]
  132. Schaiberger P. H., Kennedy T. C., Miller F. C., Gal J., Petty T. L. Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest. 1993 Aug;104(2):614–616. doi: 10.1378/chest.104.2.614. [DOI] [PubMed] [Google Scholar]
  133. Schindler M. B., Bohn D. J., Bryan A. C., Cutz E., Rabinovitch M. Increased respiratory system resistance and bronchial smooth muscle hypertrophy in children with acute postoperative pulmonary hypertension. Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1347–1352. doi: 10.1164/ajrccm.152.4.7551393. [DOI] [PubMed] [Google Scholar]
  134. Schnader J., Schloo B. L., Anderson W., Stephenson L. W., Fishman A. P. Chronic pulmonary hypertension in sheep: temporal progression of lesions. J Surg Res. 1996 May;62(2):243–250. doi: 10.1006/jsre.1996.0202. [DOI] [PubMed] [Google Scholar]
  135. Scott P. H., Peacock A. J. Cell signalling in pulmonary vascular cells: do not shoot the messenger! Thorax. 1996 Aug;51(8):864–866. doi: 10.1136/thx.51.8.864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Segall M. L., Goetzman B. W., Schick J. B. Thrombocytopenia and pulmonary hypertension in the perinatal aspiration syndromes. J Pediatr. 1980 Apr;96(4):727–730. doi: 10.1016/s0022-3476(80)80754-2. [DOI] [PubMed] [Google Scholar]
  137. Segall M., Goetzman B. Hypoxic pulmonary hypertension: changes in platelet size and number. Am J Perinatol. 1991 Sep;8(5):300–303. doi: 10.1055/s-2007-999403. [DOI] [PubMed] [Google Scholar]
  138. Seibold J. R., Molony R. R., Turkevich D., Ruddy M. C., Kostis J. B. Acute hemodynamic effects of ketanserin in pulmonary hypertension secondary to systemic sclerosis. J Rheumatol. 1987 Jun;14(3):519–524. [PubMed] [Google Scholar]
  139. Seiler K. U., Wassermann O., Wensky H. On the role of serotonin in the pathogenesis of pulmonary hypertension induced by anorectic drugs; an experimental study in the isolated perfused rat lung, II. Fenfluramine, mazindol, mefenorex, phentermine and R 800. Clin Exp Pharmacol Physiol. 1976 Jul-Aug;3(4):323–330. doi: 10.1111/j.1440-1681.1976.tb00608.x. [DOI] [PubMed] [Google Scholar]
  140. Sibbald W., Peters S., Lindsay R. M. Serotonin and pulmonary hypertension in human septic ARDS. Crit Care Med. 1980 Sep;8(9):490–494. doi: 10.1097/00003246-198009000-00003. [DOI] [PubMed] [Google Scholar]
  141. Siegal T., Pfeffer M. R. Radiation-induced changes in the profile of spinal cord serotonin, prostaglandin synthesis, and vascular permeability. Int J Radiat Oncol Biol Phys. 1995 Jan 1;31(1):57–64. doi: 10.1016/0360-3016(94)E0305-4. [DOI] [PubMed] [Google Scholar]
  142. Siegel G., Rückborn K., Schnalke F., Müller J. Endothelial dysfunction in human atherosclerotic coronary arteries. Eur Heart J. 1993 Nov;14 (Suppl 1):99–103. [PubMed] [Google Scholar]
  143. Sole M. J., Drobac M., Schwartz L., Hussain M. N., Vaughan-Neil E. F. The extraction of circulating catecholamines by the lungs in normal man and in patients with pulmonary hypertension. Circulation. 1979 Jul;60(1):160–163. doi: 10.1161/01.cir.60.1.160. [DOI] [PubMed] [Google Scholar]
  144. Spencer J. A. Paroxysmal nocturnal haemoglobinuria in pregnancy: case report. Br J Obstet Gynaecol. 1980 Mar;87(3):246–248. doi: 10.1111/j.1471-0528.1980.tb04528.x. [DOI] [PubMed] [Google Scholar]
  145. Späh F., Kottmann R., Grosser K. D., Schmidt U., Thieme G. Effects of urapidil in patients with mild pulmonary vascular hypertension. Drugs. 1990;40 (Suppl 4):69–70. doi: 10.2165/00003495-199000404-00021. [DOI] [PubMed] [Google Scholar]
  146. Stachów A., Jabłońska S., Skiendzielewska A. Biogenic amines derived from tryptophan in systemic and cutaneous scleroderma. Acta Derm Venereol. 1979;59(1):1–5. [PubMed] [Google Scholar]
  147. Steele P., Ellis J. H., Jr, Weily H. S., Genton E. Platelet survival time in patients with hypoxemia and pulmonary hypertension. Circulation. 1977 Apr;55(4):660–661. doi: 10.1161/01.cir.55.4.660. [DOI] [PubMed] [Google Scholar]
  148. Stelzner T., Hofmann T. A., Brown D., Deng A., Jacob H. J. Genetic determinants of pulmonary hypertension in fawn-hooded rats. Chest. 1997 Jun;111(6 Suppl):96S–96S. doi: 10.1378/chest.111.6_supplement.96s. [DOI] [PubMed] [Google Scholar]
  149. Steyn D. W., Odendaal H. J. Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. Lancet. 1997 Nov 1;350(9087):1267–1271. doi: 10.1016/s0140-6736(97)06408-8. [DOI] [PubMed] [Google Scholar]
  150. Svartholm E., Bergqvist D., Lindblad B., Ljungberg J., Haglund U. Pulmonary vascular response to live Escherichia coli: influences of different antiplatelet substances. Circ Shock. 1987;22(2):173–183. [PubMed] [Google Scholar]
  151. Taguchi O., Gabazza E. C., Yasui H., Kobayashi T., Yoshida M., Kobayashi H. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax. 1997 Jun;52(6):563–565. doi: 10.1136/thx.52.6.563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Takeda J., Masuda J., Fukushima K. Droperidol prevents serotonin-induced bronchospasm, pulmonary hypertension, and intrapulmonary shunt. Anesth Analg. 1992 Feb;74(2):316–316. doi: 10.1213/00000539-199202000-00038. [DOI] [PubMed] [Google Scholar]
  153. Tanabe T., Furuya H., Kanemoto N., Goto Y., Hata J. Experimental study on monocrotaline induced pulmonary hypertensive rats. (1) Effect of long-term injection of immunosuppressant. Tokai J Exp Clin Med. 1981 Jan;6(1):41–48. [PubMed] [Google Scholar]
  154. Tazelaar H. D., Myers J. L., Drage C. W., King T. E., Jr, Aguayo S., Colby T. V. Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features. Chest. 1990 May;97(5):1032–1036. doi: 10.1378/chest.97.5.1032. [DOI] [PubMed] [Google Scholar]
  155. Thomas D. P., Gurewich V., Ashford T. P. Platelet adherence to thromboemboli in relation to the pathogenesis and treatment of pulmonary embolism. N Engl J Med. 1966 Apr 28;274(17):953–956. doi: 10.1056/NEJM196604282741709. [DOI] [PubMed] [Google Scholar]
  156. Tillman B. F., Loyd J. E., Malcolm A. W., Holm B. A., Brigham K. L. Unilateral radiation pneumonitis in sheep: physiological changes and bronchoalveolar lavage. J Appl Physiol (1985) 1989 Mar;66(3):1273–1279. doi: 10.1152/jappl.1989.66.3.1273. [DOI] [PubMed] [Google Scholar]
  157. Todorovich-Hunter L., Dodo H., Ye C., McCready L., Keeley F. W., Rabinovitch M. Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease. Am Rev Respir Dis. 1992 Jul;146(1):213–223. doi: 10.1164/ajrccm/146.1.213. [DOI] [PubMed] [Google Scholar]
  158. Tomashefski J. F., Jr, Davies P., Boggis C., Greene R., Zapol W. M., Reid L. M. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol. 1983 Jul;112(1):112–126. [PMC free article] [PubMed] [Google Scholar]
  159. Tuder R. M., Groves B., Badesch D. B., Voelkel N. F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994 Feb;144(2):275–285. [PMC free article] [PubMed] [Google Scholar]
  160. Törnebrandt K., Eskilsson J., Nobin A. Heart involvement in metastatic carcinoid disease. Clin Cardiol. 1986 Jan;9(1):13–19. doi: 10.1002/clc.4960090104. [DOI] [PubMed] [Google Scholar]
  161. Van der Starre P. J., Reneman R. S. The role of serotonin blockers in cardiac anesthesia. J Cardiothorac Vasc Anesth. 1994 Aug;8(4):455–462. doi: 10.1016/1053-0770(94)90289-5. [DOI] [PubMed] [Google Scholar]
  162. Vincent J. L., Degaute J. P., Domb M., Simon P., Berre J., Vandesteene A. Ketanserin, a serotonin antagonist. Administration in patients with acute respiratory failure. Chest. 1984 Apr;85(4):510–513. doi: 10.1378/chest.85.4.510. [DOI] [PubMed] [Google Scholar]
  163. Voelkel N. F. Mechanisms of hypoxic pulmonary vasoconstriction. Am Rev Respir Dis. 1986 Jun;133(6):1186–1195. doi: 10.1164/arrd.1986.133.6.1186. [DOI] [PubMed] [Google Scholar]
  164. Weir E. K., Reeve H. L., Huang J. M., Michelakis E., Nelson D. P., Hampl V., Archer S. L. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation. 1996 Nov 1;94(9):2216–2220. doi: 10.1161/01.cir.94.9.2216. [DOI] [PubMed] [Google Scholar]
  165. Wiedemann H. P., Matthay M. A., Gillis C. N. Pulmonary endothelial cell injury and altered lung metabolic function. Early detection of the adult respiratory distress syndrome and possible functional significance. Clin Chest Med. 1990 Dec;11(4):723–736. [PubMed] [Google Scholar]
  166. Wiedemann H. P., Matthay R. A. Pulmonary manifestations of the collagen vascular diseases. Clin Chest Med. 1989 Dec;10(4):677–722. [PubMed] [Google Scholar]
  167. Williams G. D., Westbrook K. C., Campbell G. S. Reflex pulmonary hypertension and systemic hypotension after microsphere pulmonary embolism: a myth. Am J Surg. 1969 Dec;118(6):925–930. doi: 10.1016/0002-9610(69)90259-1. [DOI] [PubMed] [Google Scholar]
  168. Wilson D. W., Segall H. J., Pan L. C., Lamé M. W., Estep J. E., Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol. 1992;22(5-6):307–325. doi: 10.3109/10408449209146311. [DOI] [PubMed] [Google Scholar]
  169. Wu K. K. Platelet activation mechanisms and markers in arterial thrombosis. J Intern Med. 1996 Jan;239(1):17–34. doi: 10.1046/j.1365-2796.1996.331661000.x. [DOI] [PubMed] [Google Scholar]
  170. Zeiher A. M., Schächlinger V., Hohnloser S. H., Saurbier B., Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 1994 Jun;89(6):2525–2532. doi: 10.1161/01.cir.89.6.2525. [DOI] [PubMed] [Google Scholar]
  171. Zhang X., Ling P. Platelet activation in patients with chronic pulmonary heart disease. Effect of dipyridamole treatment. Chin Med J (Engl) 1995 Feb;108(2):95–97. [PubMed] [Google Scholar]
  172. de Kerviler E., Trédaniel J., Revlon G., Groussard O., Zalcman G., Ortoli J. M., Espié M., Hirsch A., Frija J. Fluoxetin-induced pulmonary granulomatosis. Eur Respir J. 1996 Mar;9(3):615–617. doi: 10.1183/09031936.96.09030615. [DOI] [PubMed] [Google Scholar]
  173. van der Starre P. J., Feld R. J., Reneman R. S. Ketanserin in the treatment of pulmonary hypertension after valvular surgery: a comparison with sodium nitroprusside. Crit Care Med. 1989 Jul;17(7):613–618. doi: 10.1097/00003246-198907000-00003. [DOI] [PubMed] [Google Scholar]
  174. van der Starre P. J., Solinas C. Ketanserin in the treatment of protamine-induced pulmonary hypertension. Tex Heart Inst J. 1996;23(4):301–304. [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES